These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

841 related articles for article (PubMed ID: 24231879)

  • 1. Long-term drug treatment for obesity: a systematic and clinical review.
    Yanovski SZ; Yanovski JA
    JAMA; 2014 Jan; 311(1):74-86. PubMed ID: 24231879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
    Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S
    JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A; Winterholer S; Jeitler K; Horvath K; Berghold A; Krenn C; Semlitsch T
    Cochrane Database Syst Rev; 2021 Jan; 1(1):CD007654. PubMed ID: 33454957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A; Jeitler K; Horvath K; Berghold A; Posch N; Meschik J; Semlitsch T
    Cochrane Database Syst Rev; 2016 Mar; 3():CD007654. PubMed ID: 26934640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss.
    Kelly EM; Tungol AA; Wesolowicz LA
    J Manag Care Pharm; 2013 Oct; 19(8):642-54. PubMed ID: 24074010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term pharmacotherapy for obesity and overweight.
    Padwal R; Li SK; Lau DC
    Cochrane Database Syst Rev; 2004; 2003(3):CD004094. PubMed ID: 15266516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term pharmacotherapy for obesity and overweight.
    Padwal R; Li SK; Lau DC
    Cochrane Database Syst Rev; 2003; (4):CD004094. PubMed ID: 14584004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
    Tak YJ; Lee SY
    Curr Obes Rep; 2021 Mar; 10(1):14-30. PubMed ID: 33410104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis.
    Khera R; Pandey A; Chandar AK; Murad MH; Prokop LJ; Neeland IJ; Berry JD; Camilleri M; Singh S
    Gastroenterology; 2018 Apr; 154(5):1309-1319.e7. PubMed ID: 29305933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug interventions for the treatment of obesity in children and adolescents.
    Mead E; Atkinson G; Richter B; Metzendorf MI; Baur L; Finer N; Corpeleijn E; O'Malley C; Ells LJ
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012436. PubMed ID: 27899001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
    Garvey WT; Ryan DH; Look M; Gadde KM; Allison DB; Peterson CA; Schwiers M; Day WW; Bowden CH
    Am J Clin Nutr; 2012 Feb; 95(2):297-308. PubMed ID: 22158731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination phentermine and topiramate extended release in the management of obesity.
    Alfaris N; Minnick AM; Hopkins CM; Berkowitz RI; Wadden TA
    Expert Opin Pharmacother; 2015 Jun; 16(8):1263-74. PubMed ID: 25958964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of Combining Antiobesity Medication With an Employer-Based Weight Management Program for Treatment of Obesity: A Randomized Clinical Trial.
    Pantalone KM; Smolarz BG; Ramasamy A; Baz Hecht M; Harty BJ; Rogen B; Griebeler ML; Borukh E; Young JB; Burguera B
    JAMA Netw Open; 2021 Jul; 4(7):e2116595. PubMed ID: 34255049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New obesity agents: lorcaserin and phentermine/topiramate.
    Fleming JW; McClendon KS; Riche DM
    Ann Pharmacother; 2013; 47(7-8):1007-16. PubMed ID: 23800750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis: pharmacologic treatment of obesity.
    Li Z; Maglione M; Tu W; Mojica W; Arterburn D; Shugarman LR; Hilton L; Suttorp M; Solomon V; Shekelle PG; Morton SC
    Ann Intern Med; 2005 Apr; 142(7):532-46. PubMed ID: 15809465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity.
    O'Meara S; Riemsma R; Shirran L; Mather L; ter Riet G
    Health Technol Assess; 2001; 5(18):1-81. PubMed ID: 11399238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacotherapy for obesity.
    Ioannides-Demos LL; Proietto J; McNeil JJ
    Drugs; 2005; 65(10):1391-418. PubMed ID: 15977970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings?
    Woloshin S; Schwartz LM
    JAMA Intern Med; 2014 Apr; 174(4):615-9. PubMed ID: 24515599
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 43.